Is there any risk of rebound or worsening of vitiligo symptoms after discontinuing ruxolitinib?
Featuring Cheri Frey, MD |
Assistant Professor, Dermatology & Residency Program Director
Director of Cosmentic Dermatology
Howard University
Washington, DC
Related CME
Related Media
Powered by Polaris TM